These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 1731052)

  • 1. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV; Frank JD; Craft TJ; Sundboom JL; Smith GF
    J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
    Jackson CV; Crowe VG; Craft TJ; Sundboom JL; Grinnell BW; Bobbitt JL; Burck PJ; Quay JF; Smith GF
    Circulation; 1990 Sep; 82(3):930-40. PubMed ID: 2118431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT; Driscoll EM; White AJ; Sherigill A; Giboulot TA; Lucchesi BR
    J Pharmacol Exp Ther; 2003 Aug; 306(2):616-23. PubMed ID: 12734394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis.
    Markland FS; Friedrichs GS; Pewitt SR; Lucchesi BR
    Circulation; 1994 Nov; 90(5):2448-56. PubMed ID: 7955202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y; Umemura K; Takiguchi Y; Uematsu T; Nakashima M
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):569-75. PubMed ID: 7692999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
    Martin U; Sponer G; Strein K
    J Am Coll Cardiol; 1992 Feb; 19(2):433-40. PubMed ID: 1732372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced myocardial salvage by combined treatment with recombinant single-chain urokinase-type plasminogen activator and recombinant human superoxide dismutase in a canine coronary thrombosis model.
    Fincke U; Schneider J; Friderichs E; Giertz H; Flohé L
    Arzneimittelforschung; 1988 Jan; 38(1):138-42. PubMed ID: 3365272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
    Björkman JA; Abrahamsson TI; Nerme VK; Mattsson CJ
    Thromb Res; 2005; 116(6):519-24. PubMed ID: 16181987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
    Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
    J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
    Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
    Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary artery thrombolysis: comparison of approved agents.
    Porter RS; DiPalma JR
    Am Fam Physician; 1991 Aug; 44(2):591-8. PubMed ID: 1907085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
    Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
    Bell WR
    Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis.
    Van de Werf F; Jang IK; Collen D
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.